Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pirtobrutinib + venetoclax
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Pirtobrutinib + venetoclax** is a combination of two oral small-molecule drugs used primarily in clinical research for hematologic malignancies, especially *relapsed/refractory chronic lymphocytic leukemia (CLL)* and *mantle cell lymphoma (MCL)*. Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase (BTK) inhibitor that overcomes resistance to covalent BTK inhibitors. Venetoclax is a selective B-cell lymphoma 2 (BCL-2) inhibitor that induces apoptosis in malignant cells dependent on BCL-2 for survival. The combination is designed to synergistically target two key survival pathways in CLL and MCL, and is being evaluated for fixed-duration regimens. This approach has shown deep remission rates, including high rates of undetectable minimal residual disease and complete responses in early-phase studies[1][3][5][7]. Developers of pirtobrutinib include Loxo Oncology at Lilly (a division of Eli Lilly), and venetoclax was developed by AbbVie and Genentech (a member of Roche).
- Other names
- PVpirtobrutinib plus venetoclax
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on pirtobrutinib + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pirtobrutinib + venetoclax.